AstraZeneca PLC's IO combiantion of Imfinzi and tremelimuab has failed in a Phase III study in head and neck cancer. Neither Imfinzi (durvalumab) monotherapy nor Imfinzi/tremelimumab combination treatment met the primary endpoint of overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that had progressed following platinum-based chemotherapy, in the EAGLE trial. Studies continue for in first-line head and neck cancer.
The company emphasized that the failed trial had studied the therapies in a "hard-to-treat" indication with a very poor prognosis....






